Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

More Press Releases

Frustration rules as Venezuela unveils new currency

Aug 20, 2018

CARACAS, Venezuela — Saul Jimenez just wanted to buy bread from his neighborhood bakery in Venezuela's capital on Monday. It did not go well. Banks and most other businesses were closed for the day as Venezuela launched a series of dramatic economic reforms, beginning with the release of currency with five fewer zeros in a bid to tame soaring inflation. Rampant inflation means it would take a fistful of bills to pay for a loaf of bread, so many Venezuelans like Jimenez rely on bank cards. But with banks closed to reset their systems for the change, Jimenez's cards wouldn't...

Retailers, airlines lift US stocks higher, extending gains

Aug 20, 2018

U.S. stocks moved higher in late-afternoon trading Monday, on course to extend the market's gains from last week. Investors bid up shares in big department store chains and other consumer services companies. Industrial stocks also rose, led by airlines. Energy companies climbed along with the price of U.S. crude oil. Technology stocks lagged the broader market. KEEPING SCORE: The S&P 500 index rose 8 points, or 0.3 percent, to 2,858 as of 3:25 p.m. Eastern Time. The Dow Jones Industrial Average gained 107 points, or 0.4 percent, to 25,776. The Nasdaq composite recovered from a morning slide, climbing 8 points,...

Silicon Valley vet to head women's advocacy group Catalyst

Aug 20, 2018

NEW YORK — A former Silicon Valley CEO is taking the helm of a prominent organization dedicated to the promotion of women in the workplace, saying the #MeToo era is a "fantastic time" to champion gender equality. Lorraine Hariton becomes CEO of the group Catalyst at time when sexual misconduct scandals are ensnaring corporate executives, and the departure of PepsiCo's CEO highlighted the tiny number of women leading Fortune 500 companies. But Hariton, whose appointment was announced Monday, said the #MeToo movement has pushed the spotlight on gender equality like nothing she has seen since she began her business career...

Markets Right Now: Stocks move higher on Wall Street

Aug 20, 2018

NEW YORK — The latest on developments in financial markets (all times local): 11:45 a.m. U.S. stock indexes gave up some of an early gain and are mostly higher in midday trading. Investors bid up shares in big department store chains and industrial companies Monday, adding to the market's gains from last week. Macy's jumped 4.2 percent and Boeing rose 1.5 percent. Energy stocks climbed along with the price of U.S. crude oil. Technology stocks lagged the market. Intel fell 1.7 percent. SodaStream jumped 9.6 percent after PepsiCo agreed to buy the Israeli fizzy drink maker for $3.2 billion. The...

Born out of the financial crisis, bull market nears record

Aug 20, 2018

NEW YORK — The bull market in U.S. stocks is about to become the longest in history. If stocks don't drop significantly by the close of trading Wednesday, the bull market that began in March 2009 will have lasted nine years, five months and 13 days, a record that few would have predicted when the market struggled to find its footing after a 50 percent plunge during the financial crisis. The long rally has added trillions of dollars to household wealth, helping the economy, and stands as a testament to the ability of large U.S. companies to squeeze out profits...

Subscribe to our newsletter!

Your Name

Your Email Address